📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Telmisartan to reduce insulin resistance in HIV-positive individuals on combination antiretroviral therapy: the TAILoR dose-ranging Phase II RCT (2019)

First Author: Pushpakom S

Attributed to: Renewal of the Network of Hubs for Trials Methodology Research. funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.3310/eme06060

PubMed Identifier: 31318501

Publication URI: http://europepmc.org/abstract/MED/31318501

Type: Journal Article/Review

Parent Publication: Efficacy and Mechanism Evaluation

Issue: 6